MeSH term
Frequency | Condition_Probility | Female | 379 | 0.0 |
Humans | 1126 | 0.0 |
Pregnancy | 9 | 0.0 |
Pregnancy Outcome | 2 | 0.0 |
Randomized Controlled Trials | 4 | 0.0 |
United States/epidemiology | 2 | 0.0 |
Quality Control | 2 | 1.0 |
Aged | 126 | 0.0 |
Aged, 80 and over | 28 | 0.0 |
Animals | 300 | 0.0 |
Antineoplastic Agents/*pharmacology/therapeutic use | 3 | 3.0 |
DNA Adducts | 3 | 4.0 |
DNA Damage | 5 | 0.0 |
DNA Repair | 2 | 0.0 |
Gene Expression | 29 | 0.0 |
Forecasting | 2 | 0.0 |
History, 20th Century | 2 | 1.0 |
Caffeine/*metabolism | 23 | 85.0 |
Comparative Study | 189 | 0.0 |
Cytochrome P-450 CYP1A2/*metabolism | 69 | 89.0 |
Mice | 79 | 0.0 |
Phosphodiesterase Inhibitors/metabolism | 2 | 50.0 |
Species Specificity | 50 | 1.0 |
Cytochrome P-450 CYP1A1/*biosynthesis/genetics | 2 | 8.0 |
Cytochrome P-450 CYP1A2/*biosynthesis/genetics | 2 | 66.0 |
*DNA-Binding Proteins | 9 | 0.0 |
Enzyme Induction | 46 | 7.0 |
RNA, Messenger/biosynthesis | 14 | 0.0 |
Research Support, Non-U.S. Gov't | 630 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 32 | 0.0 |
Structure-Activity Relationship | 22 | 0.0 |
Tumor Cells, Cultured | 45 | 0.0 |
Antibodies/pharmacology | 5 | 1.0 |
*Aryl Hydrocarbon Hydroxylases | 145 | 17.0 |
Cytochrome P-450 Enzyme System/antagonists & inhibitors/*metabolism | 40 | 30.0 |
Enzyme Inhibitors/pharmacology | 75 | 2.0 |
Isoenzymes/antagonists & inhibitors/metabolism | 24 | 34.0 |
Kinetics | 147 | 1.0 |
Microsomes, Liver/drug effects/*enzymology | 14 | 32.0 |
Mixed Function Oxygenases/antagonists & inhibitors/*metabolism | 11 | 23.0 |
Oxidoreductases, N-Demethylating/antagonists & inhibitors/*metabolism | 2 | 11.0 |
Transfection | 44 | 0.0 |
Amino Acid Sequence | 24 | 0.0 |
Base Sequence | 40 | 0.0 |
Cloning, Molecular | 13 | 0.0 |
Dogs | 12 | 1.0 |
Liver/enzymology | 25 | 4.0 |
Molecular Sequence Data | 50 | 0.0 |
Phylogeny | 2 | 0.0 |
RNA, Messenger/genetics/metabolism | 6 | 0.0 |
Sequence Alignment | 8 | 0.0 |
Sequence Homology, Amino Acid | 6 | 0.0 |
Cytochrome P-450 Enzyme System/*metabolism | 164 | 33.0 |
Drug Interactions | 120 | 10.0 |
Glucuronosyltransferase/*metabolism | 3 | 5.0 |
Glutathione Transferase/*metabolism | 5 | 15.0 |
Liver/drug effects/enzymology | 11 | 16.0 |
Male | 460 | 0.0 |
Mice, Inbred C57BL | 18 | 0.0 |
Oxazines/metabolism | 8 | 36.0 |
*Plant Extracts | 2 | 66.0 |
Acute Disease | 2 | 0.0 |
Adult | 289 | 0.0 |
Cytochrome P-450 CYP2D6/*metabolism | 9 | 25.0 |
Drug Therapy, Combination | 7 | 0.0 |
Middle Aged | 224 | 0.0 |
Treatment Outcome | 4 | 0.0 |
Biotransformation | 127 | 23.0 |
Imines/*metabolism | 2 | 66.0 |
Insecticides/*metabolism | 4 | 50.0 |
Isoenzymes/metabolism | 55 | 10.0 |
Oxidation-Reduction | 68 | 5.0 |
Recombinant Proteins/metabolism | 54 | 2.0 |
Research Support, U.S. Gov't, P.H.S. | 249 | 0.0 |
Solvents | 4 | 7.0 |
Spectrophotometry, Ultraviolet | 14 | 8.0 |
Substrate Specificity | 78 | 3.0 |
Cytochrome P-450 CYP1A2/*genetics | 32 | 84.0 |
Cytochrome P-450 CYP2D6/*genetics | 3 | 5.0 |
Cytochrome P-450 Enzyme System/*genetics | 27 | 6.0 |
Genotype | 70 | 0.0 |
Mixed Function Oxygenases/*genetics | 4 | 2.0 |
Pharmacogenetics | 3 | 2.0 |
Phenotype | 74 | 0.0 |
Polymorphism, Genetic/*genetics | 14 | 1.0 |
Carcinogens/pharmacokinetics | 2 | 13.0 |
Cytochrome P-450 CYP2E1/metabolism | 19 | 44.0 |
Microsomes, Liver/*enzymology | 65 | 33.0 |
Mixed Function Oxygenases/metabolism | 38 | 27.0 |
Recombinant Proteins | 5 | 0.0 |
Trihalomethanes/*pharmacokinetics | 2 | 100.0 |
Cytochrome P-450 CYP1A2/metabolism | 75 | 75.0 |
Cytochrome P-450 CYP2B1/metabolism | 3 | 27.0 |
Rats | 154 | 1.0 |
Cells, Cultured | 71 | 0.0 |
Chlorzoxazone/pharmacology | 2 | 33.0 |
Coumarins/pharmacology | 3 | 15.0 |
Enzymes/*metabolism | 2 | 13.0 |
Ketoconazole/pharmacology | 24 | 25.0 |
Mephenytoin/pharmacology | 3 | 60.0 |
Microsomes, Liver/drug effects/*metabolism | 13 | 32.0 |
Models, Biological | 11 | 0.0 |
Quinidine/pharmacology | 8 | 18.0 |
Sulfaphenazole/pharmacology | 11 | 37.0 |
Theophylline/*analogs & derivatives/pharmacology | 9 | 81.0 |
Arylamine N-Acetyltransferase/*metabolism | 9 | 28.0 |
Biological Markers | 17 | 1.0 |
Cattle | 6 | 0.0 |
Cookery | 10 | 18.0 |
Mutagenicity Tests/methods | 5 | 41.0 |
Polymorphism, Genetic | 36 | 0.0 |
Urine/chemistry | 2 | 8.0 |
Antineoplastic Agents/metabolism/*pharmacology | 2 | 7.0 |
Binding Sites | 14 | 0.0 |
Cell Division/drug effects | 5 | 0.0 |
Cytochrome P-450 CYP1A1/*biosynthesis/metabolism | 3 | 50.0 |
Cytochrome P-450 CYP1A2/*biosynthesis/metabolism | 5 | 83.0 |
DNA/drug effects/metabolism | 2 | 4.0 |
Enzyme Induction/drug effects | 39 | 10.0 |
Microsomes, Liver/metabolism | 35 | 20.0 |
Rats, Inbred F344 | 9 | 2.0 |
Aryl Hydrocarbon Hydroxylases/chemistry/*metabolism | 2 | 100.0 |
Catalysis | 29 | 3.0 |
Cytochrome P-450 Enzyme System/chemistry/*metabolism | 12 | 66.0 |
Rats, Sprague-Dawley | 52 | 2.0 |
Substrate Specificity/physiology | 3 | 13.0 |
Cytochrome P-450 Enzyme System/*isolation & purification/metabolism | 2 | 100.0 |
Area Under Curve | 38 | 8.0 |
Gene Expression Regulation, Enzymologic/*physiology | 2 | 2.0 |
*Sex Characteristics | 5 | 3.0 |
Statistics, Nonparametric | 8 | 0.0 |
Cytochrome P-450 Enzyme System/genetics/*metabolism | 44 | 29.0 |
Enzyme Induction/genetics | 5 | 31.0 |
Hepatocytes/*enzymology | 6 | 40.0 |
Omeprazole/pharmacology | 6 | 50.0 |
RNA, Messenger/*analysis | 3 | 0.0 |
Rifampin/pharmacology | 7 | 11.0 |
Sensitivity and Specificity | 18 | 0.0 |
Escherichia coli/genetics | 8 | 1.0 |
English Abstract | 23 | 0.0 |
Enzyme Inhibitors/*pharmacology | 58 | 8.0 |
Reactive Oxygen Species/*metabolism | 3 | 1.0 |
Cross-Over Studies | 38 | 6.0 |
Cytochrome P-450 Enzyme System/*antagonists & inhibitors | 43 | 36.0 |
Double-Blind Method | 15 | 0.0 |
Enzyme Inhibitors/blood/*pharmacology | 3 | 60.0 |
Itraconazole/blood/*pharmacology | 2 | 50.0 |
Africa | 2 | 2.0 |
*Gene Frequency | 2 | 0.0 |
Point Mutation | 5 | 0.0 |
*Polymorphism, Genetic | 23 | 0.0 |
Polymorphism, Single Nucleotide/*genetics | 3 | 1.0 |
Caffeine/pharmacokinetics | 5 | 38.0 |
Liver/*metabolism | 13 | 3.0 |
*Carcinogens | 2 | 6.0 |
Cell Line | 62 | 0.0 |
Cytochrome P-450 CYP1A1/genetics | 5 | 5.0 |
Hamsters | 27 | 0.0 |
Hypoxanthine Phosphoribosyltransferase/genetics | 3 | 3.0 |
Models, Chemical | 11 | 2.0 |
Mutation | 10 | 0.0 |
Time Factors | 48 | 0.0 |
Cohort Studies | 5 | 0.0 |
Gene Expression Regulation, Enzymologic | 10 | 1.0 |
Polymerase Chain Reaction | 23 | 0.0 |
Polymorphism, Single-Stranded Conformational | 4 | 0.0 |
RNA, Messenger/genetics | 7 | 0.0 |
Receptors, Aryl Hydrocarbon/*genetics | 2 | 6.0 |
Cytochrome P-450 CYP1A1/metabolism | 18 | 27.0 |
Cytochrome P-450 CYP1A2/genetics/*metabolism | 20 | 83.0 |
Cytochrome P-450 Enzyme System/metabolism | 48 | 19.0 |
DNA, Complementary/metabolism | 10 | 0.0 |
Lymphoma, Lymphoblastic | 2 | 66.0 |
Models, Molecular | 12 | 0.0 |
Mutagenesis, Site-Directed | 5 | 0.0 |
Oxazines/*metabolism | 4 | 100.0 |
Oxidoreductases/metabolism | 18 | 26.0 |
Recombinant Proteins/genetics/metabolism | 16 | 2.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 39 | 0.0 |
Anti-Infective Agents/*pharmacology | 4 | 12.0 |
Chromatography, High Pressure Liquid | 113 | 6.0 |
Cytochrome P-450 Enzyme System/*antagonists & inhibitors/metabolism | 21 | 30.0 |
In Vitro | 136 | 2.0 |
Microsomes, Liver/drug effects/enzymology | 27 | 27.0 |
Recombinant Proteins/antagonists & inhibitors | 5 | 10.0 |
*Steroid 16-alpha-Hydroxylase | 33 | 17.0 |
Steroid Hydroxylases/*antagonists & inhibitors/metabolism | 2 | 22.0 |
Imidazoles/*urine | 2 | 25.0 |
Mass Fragmentography | 13 | 6.0 |
Blotting, Northern | 11 | 0.0 |
Blotting, Western | 42 | 0.0 |
Cell Survival/drug effects | 13 | 1.0 |
Cytochrome P-450 Enzyme System/biosynthesis/*genetics | 3 | 7.0 |
Dose-Response Relationship, Drug | 74 | 1.0 |
Hepatocytes/*drug effects/enzymology | 4 | 28.0 |
Protein Isoforms | 8 | 1.0 |
RNA, Messenger/metabolism | 19 | 0.0 |
Isoenzymes/chemistry/metabolism | 3 | 10.0 |
Benzodiazepines | 9 | 42.0 |
*Smoking | 8 | 9.0 |
Aflatoxin B1/metabolism | 5 | 62.0 |
Cytochrome P-450 Enzyme System/*physiology | 22 | 37.0 |
Mice, Knockout | 8 | 0.0 |
Mice, Transgenic | 5 | 0.0 |
Mutagenicity Tests | 23 | 14.0 |
Cytochrome P-450 Enzyme System/*genetics/*metabolism | 7 | 14.0 |
Cytochrome P-450 CYP1A2/*pharmacology | 3 | 100.0 |
*DNA Adducts | 2 | 5.0 |
Kidney/enzymology | 3 | 2.0 |
Microsomes, Liver/enzymology | 69 | 31.0 |
Risk Assessment | 10 | 1.0 |
Anti-Bacterial Agents/*pharmacology | 3 | 2.0 |
Ciprofloxacin/*pharmacology | 3 | 30.0 |
Cytochrome P-450 CYP1A2/antagonists & inhibitors | 14 | 93.0 |
Half-Life | 20 | 3.0 |
Metabolic Clearance Rate | 25 | 7.0 |
Smoking/metabolism | 16 | 30.0 |
Stereoisomerism | 32 | 8.0 |
Iron/metabolism | 2 | 1.0 |
Liver/metabolism | 16 | 1.0 |
Mice, Mutant Strains | 2 | 0.0 |
Cross-Sectional Studies | 3 | 0.0 |
Ethnic Groups | 4 | 1.0 |
Enzyme Inhibitors/administration & dosage/*pharmacology | 3 | 18.0 |
Inhibitory Concentration 50 | 17 | 5.0 |
Cytochrome P-450 Enzyme System/*biosynthesis | 15 | 17.0 |
Esophagus/*enzymology | 2 | 50.0 |
Microsomes/enzymology | 20 | 19.0 |
Mixed Function Oxygenases/*biosynthesis | 3 | 15.0 |
Mouth Mucosa/*enzymology | 2 | 50.0 |
*Beverages | 5 | 11.0 |
*Citrus | 2 | 4.0 |
*Flavanones | 4 | 16.0 |
Hydrocortisone/*analogs & derivatives/urine | 2 | 13.0 |
Smoking/*blood | 2 | 8.0 |
Caffeine/metabolism | 17 | 60.0 |
Liver/*enzymology | 32 | 7.0 |
Longitudinal Studies | 3 | 0.0 |
Mephenytoin/metabolism | 7 | 43.0 |
Sparteine/metabolism | 2 | 33.0 |
Diet | 13 | 3.0 |
Flavonoids/*metabolism | 2 | 33.0 |
Cytosol/metabolism | 3 | 0.0 |
Microsomes, Liver/*metabolism | 49 | 28.0 |
Isoenzymes/antagonists & inhibitors | 11 | 26.0 |
Microsomes, Liver/drug effects/metabolism | 12 | 25.0 |
Oxidoreductases, N-Demethylating/*antagonists & inhibitors | 6 | 20.0 |
Adolescent | 73 | 0.0 |
Child | 37 | 0.0 |
Child, Preschool | 25 | 0.0 |
Cytochrome P-450 Enzyme System/*analysis | 6 | 31.0 |
Immunohistochemistry | 19 | 0.0 |
Infant | 13 | 0.0 |
Isoenzymes/*metabolism | 25 | 8.0 |
Oxidoreductases, N-Demethylating/analysis | 2 | 50.0 |
Baculoviridae/genetics | 4 | 2.0 |
Biological Markers/analysis | 3 | 0.0 |
Cytochrome P-450 Enzyme System/*biosynthesis/genetics | 12 | 17.0 |
Microsomes, Liver/*enzymology/metabolism | 9 | 31.0 |
Recombinant Proteins/biosynthesis | 5 | 1.0 |
Breast/*enzymology | 2 | 13.0 |
Cytochrome P-450 CYP1A2/genetics | 7 | 63.0 |
DNA Adducts/*analysis | 2 | 4.0 |
Glutathione Transferase/*genetics | 5 | 0.0 |
Homozygote | 6 | 0.0 |
Cell Culture Techniques | 3 | 0.0 |
Flavonoids/*pharmacology | 7 | 8.0 |
Cell Membrane/metabolism | 2 | 0.0 |
Cytochromes b5/*metabolism | 2 | 33.0 |
Escherichia coli | 3 | 0.0 |
Xenobiotics/*pharmacology | 2 | 6.0 |
Hydrocortisone/urine | 3 | 25.0 |
Insulin-Like Growth Factor I/metabolism | 3 | 1.0 |
Liver/*drug effects/enzymology | 8 | 18.0 |
Caffeine/blood/*metabolism/pharmacokinetics | 3 | 100.0 |
Central Nervous System Stimulants/*metabolism/pharmacokinetics | 2 | 100.0 |
Debrisoquin/*metabolism | 2 | 18.0 |
Enzyme Activation/drug effects | 7 | 0.0 |
Cytochrome P-450 Enzyme System/antagonists & inhibitors/*chemistry | 3 | 60.0 |
Plant Extracts/chemistry/*pharmacology | 2 | 22.0 |
Aryl Hydrocarbon Hydroxylases/genetics/*metabolism | 3 | 12.0 |
Cytochrome P-450 CYP1A1/genetics/metabolism | 8 | 26.0 |
Cytochrome P-450 CYP1A2/genetics/metabolism | 15 | 88.0 |
RNA, Messenger | 2 | 0.0 |
Retrospective Studies | 6 | 0.0 |
Arylamine N-Acetyltransferase/*genetics | 4 | 1.0 |
Case-Control Studies | 28 | 0.0 |
Colorectal Neoplasms/*genetics/metabolism | 2 | 6.0 |
*Meat | 6 | 14.0 |
Odds Ratio | 9 | 0.0 |
Quinolines/*metabolism | 4 | 23.0 |
Risk Factors | 24 | 0.0 |
Sequence Analysis, DNA | 5 | 0.0 |
Antitubercular Agents/*pharmacology | 2 | 18.0 |
Isoniazid/*pharmacology | 2 | 15.0 |
Mixed Function Oxygenases/antagonists & inhibitors | 11 | 37.0 |
NADP/metabolism | 10 | 8.0 |
Cimetidine/pharmacology | 4 | 18.0 |
Cytochrome P-450 Enzyme System/antagonists & inhibitors | 10 | 20.0 |
Ditiocarb/pharmacology | 7 | 41.0 |
Pyrazoles/pharmacology | 2 | 4.0 |
Biological Availability | 9 | 3.0 |
Magnetic Resonance Spectroscopy | 5 | 0.0 |
Microsomes, Liver/enzymology/*metabolism | 17 | 22.0 |
Oxidoreductases/antagonists & inhibitors | 3 | 42.0 |
Cytochrome P-450 CYP2D6/*antagonists & inhibitors/*metabolism | 2 | 66.0 |
Dealkylation | 28 | 49.0 |
Spectrum Analysis, Mass | 15 | 2.0 |
Isoenzymes/antagonists & inhibitors/genetics/metabolism | 6 | 42.0 |
Cytochrome P-450 Enzyme System/*biosynthesis/genetics/metabolism | 4 | 26.0 |
Enzyme Inhibitors/metabolism/pharmacology | 6 | 31.0 |
Isoenzymes/biosynthesis/genetics/metabolism | 4 | 14.0 |
Rats, Long-Evans | 2 | 4.0 |
Spectrometry, Fluorescence | 5 | 1.0 |
Cytochrome P-450 Enzyme System/*antagonists & inhibitors/chemistry | 2 | 50.0 |
Enzyme Inhibitors/chemistry/*pharmacology | 3 | 10.0 |
Fluorometry | 3 | 4.0 |
Hydroxylation | 67 | 19.0 |
Isoenzymes/genetics/metabolism | 14 | 9.0 |
Diclofenac/metabolism | 2 | 14.0 |
Phenols/*pharmacology | 2 | 5.0 |
Steroid Hydroxylases/antagonists & inhibitors | 6 | 60.0 |
Arylamine N-Acetyltransferase/*antagonists & inhibitors/metabolism | 2 | 40.0 |
Caffeine/metabolism/pharmacology | 2 | 66.0 |
Chlorzoxazone/metabolism/pharmacology | 2 | 100.0 |
Cytochrome P-450 CYP1A2/antagonists & inhibitors/metabolism | 10 | 76.0 |
Cytochrome P-450 CYP2D6/antagonists & inhibitors/metabolism | 4 | 66.0 |
Cytochrome P-450 CYP2E1/antagonists & inhibitors/metabolism | 2 | 40.0 |
Disulfiram/*pharmacology | 2 | 28.0 |
Mixed Function Oxygenases/antagonists & inhibitors/metabolism | 9 | 47.0 |
Benzo(a)pyrene/pharmacology | 2 | 9.0 |
Cytochrome P-450 CYP1A1/genetics/*metabolism | 7 | 26.0 |
DNA/metabolism | 5 | 0.0 |
Gene Expression Regulation, Enzymologic/*drug effects | 5 | 3.0 |
Nicotine/pharmacology | 2 | 22.0 |
Pyridines/pharmacology | 3 | 1.0 |
Tetrachlorodibenzodioxin/pharmacology | 5 | 6.0 |
Administration, Oral | 25 | 2.0 |
Age Factors | 13 | 0.0 |
Anti-Arrhythmia Agents/*pharmacokinetics/therapeutic use | 2 | 100.0 |
Japan | 14 | 0.0 |
Mexiletine/*pharmacokinetics/therapeutic use | 2 | 100.0 |
DNA, Complementary/genetics | 15 | 0.0 |
Mixed Function Oxygenases/antagonists & inhibitors/genetics/*metabolism | 3 | 33.0 |
Ritonavir/pharmacology | 2 | 16.0 |
5' Flanking Region/genetics | 3 | 3.0 |
Cytochrome P-450 CYP1A2/biosynthesis/*genetics | 4 | 80.0 |
Introns/*genetics | 3 | 1.0 |
Point Mutation/genetics | 2 | 0.0 |
*Food-Drug Interactions | 3 | 13.0 |
Prospective Studies | 8 | 0.0 |
Psychiatric Status Rating Scales | 5 | 2.0 |
Schizophrenia/*blood/drug therapy | 2 | 10.0 |
Alcohol Drinking/metabolism | 2 | 25.0 |
Cytochrome P-450 Enzyme System/biosynthesis/genetics/*metabolism | 6 | 37.0 |
Sex Characteristics | 9 | 1.0 |
Caffeine/diagnostic use | 4 | 40.0 |
Cytochrome P-450 CYP1A1/*physiology | 2 | 50.0 |
Nutritional Status | 2 | 1.0 |
Phosphodiesterase Inhibitors/diagnostic use | 2 | 66.0 |
Aging/*metabolism | 7 | 3.0 |
Alcohol Dehydrogenase/metabolism | 2 | 33.0 |
Mixed Function Oxygenases/*metabolism | 28 | 20.0 |
Pharmaceutical Preparations/*metabolism | 20 | 21.0 |
*Pharmacokinetics | 11 | 25.0 |
Cytochrome P-450 CYP1A1/*metabolism | 8 | 25.0 |
Mutagens/metabolism | 5 | 18.0 |
Steroid Hydroxylases/*metabolism | 8 | 25.0 |
Autoantibodies/*blood | 2 | 0.0 |
Cytochrome P-450 CYP1A2/immunology | 2 | 100.0 |
Mixed Function Oxygenases/immunology | 3 | 60.0 |
Mutagenicity Tests/*methods | 8 | 30.0 |
Recombinant Proteins/drug effects/genetics/metabolism | 2 | 12.0 |
Tobacco | 6 | 21.0 |
Coumarins/metabolism | 6 | 24.0 |
Cytochrome P-450 CYP2D6 | 16 | 21.0 |
Cytochrome P-450 Enzyme System/*genetics/metabolism | 12 | 10.0 |
Ethanolamines/metabolism | 4 | 22.0 |
Mixed Function Oxygenases/genetics | 3 | 7.0 |
NADPH-Ferrihemoprotein Reductase/*genetics/metabolism | 2 | 40.0 |
Salmonella typhimurium/*genetics | 3 | 42.0 |
Body Weight | 3 | 0.0 |
Cytochrome P-450 Enzyme System/physiology | 4 | 15.0 |
Liver/drug effects/metabolism | 5 | 7.0 |
Pharmacokinetics | 9 | 25.0 |
Acetaminophen/metabolism | 2 | 40.0 |
Phenacetin/metabolism/pharmacology | 2 | 100.0 |
Quinine/pharmacology | 2 | 15.0 |
Recombinant Proteins/antagonists & inhibitors/genetics/metabolism | 6 | 20.0 |
Liver Neoplasms/*metabolism | 2 | 2.0 |
Metabolic Detoxication, Drug | 4 | 4.0 |
Clozapine/blood/*therapeutic use | 2 | 100.0 |
Cytochrome P-450 CYP1A2/*genetics/*metabolism | 4 | 100.0 |
Arylamine N-Acetyltransferase/metabolism | 12 | 57.0 |
Biological Markers/urine | 2 | 3.0 |
*Diet | 11 | 5.0 |
Theophylline/urine | 5 | 83.0 |
Uric Acid/*analogs & derivatives/urine | 4 | 80.0 |
Xanthines/urine | 7 | 53.0 |
Anticonvulsants/metabolism/*pharmacology | 2 | 100.0 |
Enzyme Inhibitors/metabolism/*pharmacology | 2 | 11.0 |
Microsomes, Liver/drug effects/*enzymology/metabolism | 2 | 22.0 |
Rats, Wistar | 21 | 1.0 |
Biotransformation/drug effects | 7 | 24.0 |
Hepatocytes/drug effects/*metabolism | 2 | 13.0 |
Spectrometry, Mass, Electrospray Ionization | 4 | 4.0 |
European Continental Ancestry Group/genetics | 4 | 0.0 |
Pregnancy Trimester, First | 3 | 1.0 |
Sweden | 3 | 1.0 |
DNA Adducts/*metabolism | 5 | 10.0 |
Microsomes, Liver/*drug effects/metabolism | 4 | 30.0 |
Rabbits | 35 | 1.0 |
Aflatoxin B1/metabolism/*toxicity | 3 | 100.0 |
Cytochrome P-450 CYP1A2/drug effects/genetics/metabolism | 2 | 100.0 |
DNA Adducts/drug effects | 2 | 50.0 |
Plasmids | 6 | 0.0 |
Anticarcinogenic Agents/*pharmacology | 8 | 8.0 |
Cells, Cultured/drug effects | 2 | 2.0 |
Comet Assay | 3 | 4.0 |
Cricetulus | 8 | 1.0 |
DNA Adducts/analysis | 2 | 15.0 |
Quercetin/*pharmacology | 2 | 8.0 |
Antineoplastic Agents/*pharmacokinetics | 3 | 23.0 |
Cytosol/enzymology | 3 | 1.0 |
Arylamine N-Acetyltransferase/*genetics/metabolism | 5 | 9.0 |
Colorectal Neoplasms/*etiology/genetics | 2 | 66.0 |
Cytochrome P-450 CYP1A2/*genetics/metabolism | 8 | 100.0 |
*Genetic Predisposition to Disease | 5 | 0.0 |
Smoking/*adverse effects | 5 | 2.0 |
Guinea Pigs | 8 | 0.0 |
Macaca fascicularis | 12 | 4.0 |
Protein Binding | 21 | 0.0 |
Cytochrome P-450 Enzyme System/*chemistry | 2 | 16.0 |
Heme/chemistry | 2 | 9.0 |
Protein Conformation | 4 | 0.0 |
Spectrophotometry | 4 | 2.0 |
Aryl Hydrocarbon Hydroxylases/metabolism | 13 | 28.0 |
Asian Continental Ancestry Group | 2 | 0.0 |
China | 8 | 1.0 |
Sex Factors | 18 | 1.0 |
Acetyltransferases/genetics/metabolism | 3 | 27.0 |
Arylamine N-Acetyltransferase/genetics/metabolism | 6 | 40.0 |
Glutathione Transferase/genetics/metabolism | 3 | 2.0 |
Quinolines/*pharmacokinetics | 5 | 50.0 |
Cytochrome P-450 CYP1A2/*physiology | 7 | 100.0 |
Estradiol/*analogs & derivatives/biosynthesis/*metabolism | 2 | 100.0 |
Estradiol/metabolism | 2 | 2.0 |
Fetus/metabolism | 2 | 1.0 |
Isomerism | 5 | 2.0 |
*Point Mutation | 3 | 0.0 |
Testosterone/metabolism | 7 | 5.0 |
Tissue Distribution | 13 | 0.0 |
DNA Primers/genetics | 4 | 0.0 |
Multigene Family | 3 | 0.0 |
Xenobiotics/metabolism | 4 | 9.0 |
Bronchodilator Agents/administration & dosage/blood/*pharmacokinetics | 2 | 100.0 |
Theophylline/administration & dosage/blood/*pharmacokinetics | 3 | 100.0 |
Hydroxylation/drug effects | 9 | 25.0 |
Microsomes, Liver/*drug effects/enzymology | 14 | 41.0 |
Steroid Hydroxylases/antagonists & inhibitors/metabolism | 5 | 55.0 |
Tolbutamide/metabolism | 4 | 26.0 |
Drug Monitoring | 3 | 6.0 |
Dietary Supplements/*toxicity | 2 | 100.0 |
*Herb-Drug Interactions | 2 | 66.0 |
Korea | 2 | 0.0 |
Obesity/drug therapy | 2 | 50.0 |
Plant Extracts/*toxicity | 3 | 60.0 |
Chlorzoxazone/metabolism | 7 | 35.0 |
Cytochrome P-450 CYP2D6/metabolism | 21 | 52.0 |
Midazolam/metabolism | 4 | 20.0 |
Omeprazole/metabolism | 2 | 25.0 |
Oxidoreductases, N-Demethylating/metabolism | 8 | 15.0 |
Cytochrome P-450 CYP1A2/*antagonists & inhibitors | 13 | 86.0 |
Fluvoxamine/metabolism/*pharmacology | 2 | 100.0 |
Theophylline/*pharmacokinetics | 2 | 33.0 |
Antipsychotic Agents/*pharmacokinetics | 3 | 50.0 |
Cytochrome P-450 Enzyme System/biosynthesis/*metabolism | 12 | 48.0 |
DNA, Complementary/biosynthesis | 6 | 10.0 |
Haloperidol/*pharmacokinetics | 2 | 100.0 |
Steroid Hydroxylases/metabolism | 12 | 19.0 |
Binding, Competitive | 9 | 0.0 |
Cytochrome P-450 CYP1A1/antagonists & inhibitors/metabolism | 5 | 55.0 |
Cytochrome P-450 CYP1A2/*antagonists & inhibitors/metabolism | 10 | 90.0 |
Cytochrome P-450 Enzyme System/antagonists & inhibitors/metabolism | 9 | 25.0 |
Microsomes, Liver/drug effects/enzymology/metabolism | 7 | 23.0 |
Stilbenes/*pharmacology | 2 | 3.0 |
Insecticides/*pharmacokinetics | 2 | 66.0 |
Recombinant Proteins/pharmacokinetics | 2 | 11.0 |
Troleandomycin/pharmacology | 9 | 15.0 |
Smoking | 14 | 3.0 |
Benzoflavones/pharmacology | 17 | 34.0 |
Cytochrome P-450 CYP1A2/antagonists & inhibitors/*metabolism | 11 | 84.0 |
Liver/drug effects/*metabolism | 2 | 2.0 |
Cytochrome P-450 CYP2D6/genetics/*metabolism | 4 | 28.0 |
Isoenzymes | 8 | 4.0 |
Micronucleus Tests | 4 | 8.0 |
Carbon Isotopes | 4 | 7.0 |
Chromatography, High Pressure Liquid/methods | 6 | 4.0 |
Reproducibility of Results | 17 | 1.0 |
Oxidoreductases, N-Demethylating/*metabolism | 11 | 13.0 |
Saccharomyces cerevisiae/enzymology | 2 | 3.0 |
Hydrogen-Ion Concentration | 3 | 0.0 |
Cytochrome P-450 CYP2E1/genetics/metabolism | 7 | 58.0 |
Genetic Engineering | 6 | 6.0 |
Mixed Function Oxygenases/genetics/metabolism | 8 | 36.0 |
NADPH-Ferrihemoprotein Reductase/genetics/metabolism | 2 | 28.0 |
Salmonella typhimurium/drug effects/genetics | 4 | 28.0 |
RNA, Messenger/analysis | 13 | 0.0 |
Reference Standards | 2 | 0.0 |
Transcription, Genetic | 9 | 0.0 |
Aging | 3 | 0.0 |
Fluvoxamine/*pharmacology | 18 | 72.0 |
Models, Statistical | 3 | 1.0 |
Molecular Probes | 5 | 8.0 |
Phenacetin/metabolism/pharmacokinetics | 2 | 100.0 |
Caffeine/*metabolism/urine | 3 | 50.0 |
Uracil/*analogs & derivatives/urine | 3 | 75.0 |
Xanthine Oxidase/*metabolism | 10 | 58.0 |
Biopsy | 5 | 0.0 |
Cell Differentiation | 5 | 0.0 |
In Situ Hybridization | 3 | 0.0 |
Cytochrome P-450 CYP1A2/*biosynthesis | 10 | 90.0 |
Gene Expression Profiling | 3 | 0.0 |
Microsomes, Liver/chemistry/enzymology | 5 | 83.0 |
Mixed Function Oxygenases/chemistry/*metabolism | 2 | 50.0 |
Analysis of Variance | 16 | 0.0 |
Cytochrome P-450 CYP1A1/drug effects/metabolism | 2 | 33.0 |
Cytochrome P-450 CYP1A2/drug effects/metabolism | 3 | 60.0 |
Cytochrome P-450 Enzyme System/drug effects/*metabolism | 7 | 31.0 |
Environmental Exposure | 4 | 2.0 |
Mixed Function Oxygenases/drug effects/metabolism | 2 | 40.0 |
Algorithms | 12 | 3.0 |
Biological Markers/blood | 3 | 0.0 |
*Brassica | 2 | 25.0 |
DNA/blood | 2 | 1.0 |
Lymphocytes/metabolism | 2 | 0.0 |
Meat | 6 | 18.0 |
Autoantigens/*immunology | 2 | 1.0 |
Fluorescent Antibody Technique, Indirect | 4 | 0.0 |
Liver/*immunology | 2 | 5.0 |
Recombinant Proteins/immunology | 3 | 0.0 |
Cytochrome P-450 Enzyme System/genetics/*physiology | 4 | 36.0 |
Cytochrome P-450 Enzyme System/antagonists & inhibitors/physiology | 2 | 66.0 |
Fluvoxamine/pharmacokinetics/pharmacology | 2 | 100.0 |
Insects | 5 | 2.0 |
Microsomes/metabolism | 9 | 7.0 |
Phenobarbital/pharmacology | 5 | 8.0 |
Antipsychotic Agents/*metabolism | 4 | 66.0 |
Cytochrome P-450 CYP1A2/physiology | 4 | 66.0 |
Cytochrome P-450 CYP2D6/physiology | 4 | 57.0 |
Mixed Function Oxygenases/physiology | 6 | 50.0 |
Hepatocytes/metabolism | 3 | 3.0 |
Piperazines/*metabolism | 3 | 60.0 |
Alleles | 21 | 0.0 |
Carcinogens/*metabolism | 18 | 23.0 |
Polycyclic Hydrocarbons, Aromatic/*metabolism | 2 | 11.0 |
Recombinant Proteins/pharmacology | 5 | 0.0 |
Cytochrome P-450 CYP2D6/antagonists & inhibitors | 4 | 57.0 |
Histamine H1 Antagonists/*pharmacology | 2 | 18.0 |
Genetic Predisposition to Disease | 10 | 0.0 |
European Continental Ancestry Group | 6 | 0.0 |
Gene Frequency | 13 | 0.0 |
*Polymorphism, Restriction Fragment Length | 3 | 0.0 |
DNA/analysis | 2 | 0.0 |
DNA Primers/chemistry | 5 | 0.0 |
*Gene Expression Regulation, Enzymologic | 9 | 1.0 |
RNA/analysis | 3 | 1.0 |
Benzo(a)pyrene/metabolism | 4 | 22.0 |
Fluorenes/metabolism | 2 | 18.0 |
Lung/*enzymology | 2 | 3.0 |
Prodrugs/metabolism | 2 | 50.0 |
Quinolines/metabolism | 4 | 36.0 |
Phosphodiesterase Inhibitors/*diagnostic use | 2 | 100.0 |
Reference Values | 40 | 0.0 |
Cholesterol/biosynthesis | 2 | 13.0 |
Imidazoles/*pharmacology | 2 | 2.0 |
Kidney/metabolism | 4 | 1.0 |
Pharmaceutical Preparations/metabolism | 7 | 21.0 |
Placenta/metabolism | 2 | 1.0 |
Triazoles/*pharmacology | 3 | 23.0 |
Caffeine/*pharmacology | 2 | 10.0 |
Cytochrome P-450 Enzyme System/*drug effects | 4 | 30.0 |
Drug Combinations | 6 | 1.0 |
Pilot Projects | 4 | 0.0 |
Comorbidity | 2 | 0.0 |
Drug Administration Schedule | 2 | 0.0 |
Caffeine/*blood | 3 | 75.0 |
Smoking/*genetics | 2 | 4.0 |
Beverages | 3 | 11.0 |
Enzyme Activation | 12 | 0.0 |
NADPH-Ferrihemoprotein Reductase/metabolism | 4 | 17.0 |
Cytochrome P-450 CYP1A2/*antagonists & inhibitors/*metabolism | 2 | 66.0 |
Microsomes, Liver/enzymology/metabolism | 20 | 30.0 |
Phenacetin/metabolism | 10 | 90.0 |
Methylation | 20 | 3.0 |
Pyrazines/*pharmacology | 2 | 6.0 |
Theophylline/metabolism | 11 | 84.0 |
Binding, Competitive/drug effects | 2 | 3.0 |
Thiocyanates/*pharmacology | 2 | 16.0 |
Molecular Structure | 9 | 1.0 |
Yeasts/enzymology | 2 | 22.0 |
Antibodies | 2 | 0.0 |
Hydrolysis | 3 | 0.0 |
Microsomes, Liver | 3 | 30.0 |
Caffeine/blood | 4 | 100.0 |
Theophylline/blood | 4 | 100.0 |
Variation (Genetics) | 9 | 0.0 |
Infant, Newborn | 10 | 0.0 |
*Models, Biological | 4 | 2.0 |
Probability | 3 | 0.0 |
Theobromine/administration & dosage/pharmacokinetics | 2 | 100.0 |
Cytochrome P-450 CYP1A2/analysis/*metabolism | 2 | 100.0 |
Uracil/analogs & derivatives/urine | 3 | 37.0 |
Cytochrome P-450 CYP1A2/biosynthesis/blood/*genetics | 2 | 100.0 |
Smoking/blood/genetics | 2 | 40.0 |
Acetyltransferases/genetics/*metabolism | 3 | 12.0 |
Carcinogens/*toxicity | 10 | 9.0 |
Heterocyclic Compounds/*toxicity | 2 | 20.0 |
Mutagens/*toxicity | 7 | 6.0 |
NADPH-Ferrihemoprotein Reductase/genetics/*metabolism | 5 | 50.0 |
Epithelial Cells/enzymology | 3 | 8.0 |
Isoenzymes/antagonists & inhibitors/genetics/*metabolism | 3 | 21.0 |
*Transfection | 2 | 0.0 |
Xenobiotics/toxicity | 2 | 25.0 |
Gene Expression Regulation, Enzymologic/drug effects | 5 | 3.0 |
Glucuronosyltransferase/genetics/*metabolism | 2 | 5.0 |
Confidence Intervals | 7 | 2.0 |
Cytochrome P-450 Enzyme System/*antagonists & inhibitors/*metabolism | 8 | 28.0 |
Drug Interactions/physiology | 5 | 15.0 |
Antibody Specificity | 9 | 0.0 |
Hepatocytes/cytology/drug effects/*metabolism | 2 | 25.0 |
Immunoblotting | 21 | 0.0 |
Warfarin/metabolism | 3 | 20.0 |
Carcinoma, Hepatocellular | 3 | 0.0 |
Cytochrome P-450 Enzyme System/genetics/metabolism | 7 | 15.0 |
Cytochrome P-450 Enzyme System/genetics | 4 | 3.0 |
Caffeine/*pharmacokinetics | 13 | 76.0 |
Cytochrome P-450 Enzyme System/antagonists & inhibitors/*physiology | 4 | 26.0 |
Mephenytoin/*pharmacokinetics | 2 | 40.0 |
Mixed Function Oxygenases/antagonists & inhibitors/*physiology | 3 | 50.0 |
Predictive Value of Tests | 9 | 0.0 |
Drug Evaluation, Preclinical | 2 | 1.0 |
Microsomes, Liver/drug effects | 3 | 50.0 |
Mixed Function Oxygenases/*antagonists & inhibitors | 10 | 23.0 |
DNA, Complementary | 19 | 0.0 |
Cytochrome P-450 CYP1A2/biosynthesis/*metabolism | 5 | 100.0 |
Prodrugs/*pharmacokinetics | 3 | 27.0 |
Cell Fractionation | 3 | 1.0 |
Isoenzymes/*biosynthesis | 4 | 6.0 |
United States | 3 | 0.0 |
Gene Targeting/*methods | 2 | 9.0 |
*Recombination, Genetic | 2 | 0.0 |
Cytochrome P-450 Enzyme System/drug effects/*physiology | 3 | 100.0 |
Melatonin/*analogs & derivatives/*metabolism | 2 | 100.0 |
Serotonin Uptake Inhibitors/*pharmacology | 19 | 63.0 |
Liver/drug effects/*enzymology | 5 | 12.0 |
Xenobiotics/*metabolism | 13 | 24.0 |
B-Lymphocytes/enzymology | 4 | 11.0 |
Coumarins/*pharmacokinetics | 2 | 100.0 |
Omeprazole/*pharmacology | 6 | 25.0 |
Random Allocation | 4 | 0.0 |
Phenacetin/*metabolism | 3 | 75.0 |
Hawaii/epidemiology | 3 | 20.0 |
Incidence | 2 | 0.0 |
Logistic Models | 5 | 0.0 |
Multivariate Analysis | 3 | 0.0 |
Smoking/epidemiology | 2 | 3.0 |
Caffeine/urine | 3 | 75.0 |
Cytochrome P-450 CYP1A1/*genetics | 5 | 2.0 |
Cytochrome P-450 CYP2E1/*genetics | 4 | 3.0 |
Antidepressive Agents, Second-Generation/*pharmacology | 4 | 44.0 |
Cytochrome P-450 CYP1A2/drug effects/*metabolism | 4 | 100.0 |
Theophylline/analogs & derivatives/pharmacology | 14 | 63.0 |
Cyclosporine/pharmacology | 2 | 0.0 |
Liver Function Tests | 3 | 1.0 |
Uracil/analogs & derivatives/metabolism | 2 | 66.0 |
Xanthine Oxidase/metabolism | 7 | 36.0 |
Liver/enzymology/*metabolism | 3 | 8.0 |
Asian Continental Ancestry Group/*genetics | 4 | 1.0 |
DNA Primers | 16 | 0.0 |
Ethanolamines/*pharmacokinetics | 2 | 100.0 |
European Continental Ancestry Group/*genetics | 3 | 0.0 |
Mixed Function Oxygenases/drug effects/*metabolism | 2 | 33.0 |
Statistics | 5 | 1.0 |
Callithrix | 5 | 7.0 |
Tetrachlorodibenzodioxin | 3 | 42.0 |
Disease Susceptibility | 5 | 0.0 |
Brain/*enzymology | 3 | 1.0 |
Molecular Conformation | 2 | 0.0 |
Anti-Arrhythmia Agents/blood/*pharmacokinetics | 2 | 100.0 |
Metabolic Clearance Rate/drug effects | 2 | 12.0 |
Mixed Function Oxygenases/*antagonists & inhibitors/metabolism | 4 | 12.0 |
Biological Assay/methods | 2 | 5.0 |
*Gene Expression Regulation | 2 | 0.0 |
Restriction Mapping | 2 | 0.0 |
Caffeine/*metabolism/pharmacokinetics | 2 | 100.0 |
Severity of Illness Index | 2 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 7 | 0.0 |
Aging/metabolism | 3 | 1.0 |
Intestinal Absorption | 3 | 2.0 |
Metabolism/*genetics | 2 | 33.0 |
Cell Line, Transformed | 4 | 0.0 |
Thiazoles/*metabolism | 3 | 23.0 |
African Continental Ancestry Group/genetics | 2 | 0.0 |
Asian Continental Ancestry Group/genetics | 5 | 1.0 |
*Monoterpenes | 3 | 30.0 |
Terpenes/pharmacology | 2 | 7.0 |
Caffeine/administration & dosage/*pharmacokinetics | 2 | 66.0 |
Central Nervous System Stimulants/*pharmacokinetics | 8 | 88.0 |
Linear Models | 2 | 0.0 |
Sampling Studies | 2 | 1.0 |
*Cryopreservation | 3 | 4.0 |
Hepatocytes/*metabolism | 2 | 4.0 |
Metabolic Clearance Rate/*physiology | 2 | 66.0 |
Lung/*metabolism | 2 | 2.0 |
Carcinogens, Environmental/pharmacokinetics/*toxicity | 2 | 100.0 |
Neoplasms/*enzymology | 2 | 5.0 |
Acetonitriles/pharmacology | 2 | 50.0 |
Dimethyl Sulfoxide/pharmacology | 3 | 3.0 |
Ethanol/pharmacology | 3 | 4.0 |
Hepatocytes/*drug effects/*enzymology | 4 | 57.0 |
Methanol/pharmacology | 2 | 18.0 |
Solvents/*pharmacology | 2 | 20.0 |
Cell Line/enzymology | 2 | 50.0 |
Haloperidol/*analogs & derivatives/metabolism | 2 | 100.0 |
7-Alkoxycoumarin O-Dealkylase/metabolism | 3 | 60.0 |
Introns | 2 | 0.0 |
Biological Transport | 4 | 0.0 |
Cytochrome P-450 CYP1A1/*biosynthesis | 4 | 16.0 |
Receptors, Aryl Hydrocarbon/genetics/*physiology | 3 | 60.0 |
Transcription Factors/genetics | 3 | 0.0 |
Protein Isoforms/metabolism | 2 | 1.0 |
Cytochrome P-450 Enzyme System/immunology/*metabolism | 5 | 33.0 |
Drug Synergism | 4 | 0.0 |
Plants, Toxic | 5 | 12.0 |
Recombinant Fusion Proteins/genetics/metabolism | 3 | 0.0 |
Administration, Cutaneous | 2 | 2.0 |
Safety | 2 | 1.0 |
Carcinogens/*metabolism/*toxicity | 2 | 50.0 |
Cytochrome P-450 CYP2E1/*physiology | 2 | 28.0 |
Disease Models, Animal | 2 | 0.0 |
Anti-HIV Agents/*pharmacology | 2 | 1.0 |
Cytochrome P-450 CYP2D6/*antagonists & inhibitors | 4 | 44.0 |
Enzyme Inhibitors/pharmacokinetics/*pharmacology | 2 | 18.0 |
Chromatography, Liquid/*methods | 2 | 12.0 |
Combined Modality Therapy | 3 | 0.0 |
Depressive Disorder/drug therapy | 3 | 50.0 |
Alkylation | 5 | 7.0 |
Proteins/metabolism | 3 | 0.0 |
Cytochrome P-450 Enzyme System/biosynthesis/immunology/*metabolism | 2 | 100.0 |
Cytochromes b5/metabolism | 3 | 37.0 |
DNA, Complementary/*biosynthesis | 6 | 50.0 |
Data Interpretation, Statistical | 4 | 1.0 |
Immunochemistry | 4 | 1.0 |
Baculoviridae/metabolism | 2 | 7.0 |
Prodrugs/*metabolism | 2 | 40.0 |
Subcellular Fractions/metabolism | 2 | 0.0 |
*Xanthones | 4 | 28.0 |
Drug Evaluation, Preclinical/*methods | 3 | 9.0 |
Arylamine N-Acetyltransferase/genetics | 4 | 6.0 |
Carcinoma, Hepatocellular/enzymology | 3 | 16.0 |
Gene Expression/*drug effects | 2 | 0.0 |
Liver Neoplasms/enzymology | 3 | 21.0 |
Plant Extracts/*pharmacology | 7 | 9.0 |
Fluvoxamine/administration & dosage/*pharmacology | 2 | 100.0 |
Biotransformation/*drug effects | 3 | 75.0 |
Quinolines/metabolism/*pharmacokinetics | 2 | 100.0 |
Salmonella typhimurium/genetics | 2 | 14.0 |
Spodoptera | 2 | 0.0 |
Clinical Trials | 5 | 0.0 |
Enzyme Inhibitors/*adverse effects/pharmacokinetics/pharmacology | 2 | 100.0 |
Caffeine/blood/*pharmacokinetics | 5 | 100.0 |
Central Nervous System Stimulants/blood/*pharmacokinetics | 2 | 100.0 |
Molecular Biology | 2 | 0.0 |
Indicators and Reagents | 6 | 2.0 |
Liver/cytology/drug effects/metabolism | 2 | 16.0 |
Theophylline/pharmacokinetics | 2 | 28.0 |
Fetus | 3 | 0.0 |
Gestational Age | 3 | 0.0 |
Anti-Infective Agents/*pharmacokinetics | 2 | 66.0 |
Carbon Radioisotopes/diagnostic use | 2 | 3.0 |
*Oxazolidinones | 2 | 50.0 |
Serotonin Uptake Inhibitors/*pharmacokinetics/therapeutic use | 3 | 75.0 |
Cytochrome P-450 CYP2D6/antagonists & inhibitors/*metabolism | 2 | 40.0 |
*European Continental Ancestry Group | 4 | 4.0 |
Aryl Hydrocarbon Hydroxylases/*metabolism | 7 | 14.0 |
Crystallography, X-Ray | 2 | 0.0 |
Hydrogen Bonding | 3 | 1.0 |
Ligands | 4 | 0.0 |
Saliva/*metabolism | 3 | 9.0 |
Isoenzymes/biosynthesis/metabolism | 2 | 22.0 |
Liver/drug effects/enzymology/metabolism | 3 | 25.0 |
Cell Division | 3 | 0.0 |
Cytochrome P-450 CYP1A2/biosynthesis | 10 | 83.0 |
Mixed Function Oxygenases/biosynthesis | 3 | 21.0 |
Depression, Chemical | 3 | 1.0 |
Propafenone/*metabolism | 2 | 100.0 |
Gene Expression/drug effects | 4 | 0.0 |
Anti-Arrhythmia Agents/metabolism | 2 | 100.0 |
Mixed Function Oxygenases/genetics/*metabolism | 7 | 14.0 |
Schizophrenia/drug therapy/*genetics | 2 | 12.0 |
Isoenzymes/antagonists & inhibitors/*metabolism | 5 | 13.0 |
Tetrazoles/*metabolism | 2 | 66.0 |
Antidepressive Agents, Second-Generation/blood/*pharmacology | 2 | 66.0 |
Fluvoxamine/blood/*pharmacology | 2 | 100.0 |
Serotonin Uptake Inhibitors/blood/*pharmacology | 2 | 100.0 |
Microsomes, Liver/*drug effects/*metabolism | 2 | 40.0 |
Serotonin Antagonists/*pharmacokinetics | 2 | 50.0 |
Serotonin Uptake Inhibitors/*pharmacokinetics | 3 | 60.0 |
Alkane 1-Monooxygenase | 3 | 9.0 |
Clofibrate/pharmacology | 4 | 19.0 |
Dexamethasone/pharmacology | 5 | 1.0 |
Liver/*drug effects/*metabolism | 2 | 16.0 |
Nucleic Acid Hybridization | 4 | 0.0 |
Methylcholanthrene/pharmacology | 5 | 14.0 |
beta-Naphthoflavone/pharmacology | 5 | 17.0 |
Antidepressive Agents/*pharmacology | 5 | 18.0 |
*Hypericum | 3 | 33.0 |
Plant Extracts/pharmacology | 2 | 5.0 |
*Plants, Medicinal | 3 | 4.0 |
Isoenzymes/*antagonists & inhibitors | 7 | 21.0 |
Fluvoxamine/pharmacology | 10 | 71.0 |
Citrus/*metabolism | 3 | 60.0 |
Enzyme-Linked Immunosorbent Assay | 5 | 0.0 |
Peptides/*immunology | 2 | 2.0 |
Microsomes/*enzymology | 5 | 11.0 |
Life Style | 3 | 2.0 |
Saliva/metabolism | 5 | 16.0 |
Acetylation | 10 | 1.0 |
Carcinogens/*pharmacokinetics | 4 | 17.0 |
Imidazoles/*pharmacokinetics | 3 | 21.0 |
Glutathione Transferase/genetics | 2 | 0.0 |
*Vegetables | 4 | 30.0 |
Body Weight/drug effects | 3 | 1.0 |
Carcinogenicity Tests | 3 | 3.0 |
*Gene Expression | 5 | 0.0 |
Lymphocytes/*metabolism | 2 | 1.0 |
RNA, Messenger/*biosynthesis | 3 | 1.0 |
Cytochrome P-450 CYP2D6/*physiology | 3 | 50.0 |
Dextromethorphan/*metabolism | 2 | 50.0 |
Swine | 4 | 0.0 |
Molecular Probes/metabolism | 2 | 66.0 |
*Phenotype | 6 | 2.0 |
Designer Drugs/*metabolism | 2 | 100.0 |
*Drug Monitoring | 2 | 10.0 |
Cytochrome P-450 CYP2D6/*antagonists & inhibitors/metabolism | 3 | 60.0 |
Immunization | 2 | 0.0 |
Sulfoxides/metabolism | 2 | 50.0 |
Dioxins/*pharmacology | 2 | 14.0 |
Anticonvulsants/metabolism | 2 | 33.0 |
Antitussive Agents/metabolism | 2 | 50.0 |
Dextromethorphan/metabolism | 5 | 45.0 |
Hypoglycemic Agents/metabolism | 2 | 50.0 |
Oxygenases/antagonists & inhibitors/*metabolism | 2 | 33.0 |
Rosales/*chemistry | 2 | 40.0 |
Carcinogens/*pharmacology | 2 | 3.0 |
Cytochrome P-450 CYP2E1/*metabolism | 3 | 5.0 |
*Asian Continental Ancestry Group | 2 | 3.0 |
Caffeine/*urine | 5 | 100.0 |
Smoking/*metabolism/urine | 2 | 100.0 |
Environmental Pollutants/metabolism/*toxicity | 2 | 66.0 |
Liver/cytology/*drug effects/*enzymology | 2 | 50.0 |
Receptors, Aryl Hydrocarbon/metabolism | 2 | 5.0 |
Tetrachlorodibenzodioxin/metabolism/*toxicity | 3 | 60.0 |
Tritium | 2 | 0.0 |
Imidazoles/*toxicity | 2 | 4.0 |
DNA/biosynthesis | 2 | 0.0 |
DNA Footprinting | 2 | 0.0 |
DNA-Binding Proteins/*metabolism | 2 | 0.0 |
Olfactory Mucosa/*enzymology | 2 | 100.0 |
*Promoter Regions (Genetics) | 3 | 0.0 |
Trans-Activation (Genetics) | 3 | 0.0 |
*Transcription Factors | 2 | 0.0 |
Cytochrome P-450 Enzyme System/drug effects | 4 | 40.0 |
Herb-Drug Interactions | 4 | 50.0 |
Mixed Function Oxygenases/drug effects | 3 | 75.0 |
Arylamine N-Acetyltransferase/genetics/*metabolism | 6 | 37.0 |
Central Nervous System Stimulants/*metabolism | 3 | 75.0 |
P-Glycoprotein/metabolism | 2 | 3.0 |
Chromatography, Liquid | 4 | 3.0 |
NADP/pharmacology | 5 | 22.0 |
Tretinoin/*metabolism | 2 | 4.0 |
Serotonin Uptake Inhibitors/blood/*pharmacokinetics | 2 | 100.0 |
Gene Expression Regulation, Neoplastic | 2 | 0.0 |
Liver Neoplasms | 2 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction/methods | 2 | 0.0 |
*Transcription, Genetic | 2 | 0.0 |
Cytochrome P-450 CYP1A2/drug effects/genetics/*metabolism | 2 | 100.0 |
Theophylline/blood/metabolism | 2 | 66.0 |
Cytochrome P-450 CYP1A2/drug effects | 2 | 100.0 |
Cytochrome P-450 CYP2D6/drug effects | 2 | 100.0 |
Cytochrome P-450 Enzyme System/*drug effects/metabolism | 2 | 14.0 |
Hemoglobins/metabolism | 2 | 1.0 |
Steroid Hydroxylases/drug effects | 2 | 66.0 |
Clozapine/*pharmacokinetics | 2 | 50.0 |
Cell Line, Tumor | 6 | 0.0 |
Micronucleus Tests/*methods | 2 | 100.0 |
Mutagens | 2 | 6.0 |
Estradiol/*metabolism | 3 | 4.0 |
Estrone/*metabolism | 2 | 33.0 |
Antipsychotic Agents/blood/*pharmacokinetics | 4 | 66.0 |
Clozapine/blood/*pharmacokinetics | 3 | 100.0 |
Food Contamination | 3 | 10.0 |
Microsomes | 2 | 14.0 |
Cholinesterase Inhibitors/blood/*pharmacokinetics/urine | 2 | 100.0 |
Cytochrome P-450 CYP1A2/*drug effects/metabolism | 4 | 100.0 |
Erythromycin/*pharmacology | 3 | 14.0 |
Glutathione/metabolism | 4 | 1.0 |
Oxidative Stress/*physiology | 2 | 2.0 |
Signal Transduction | 2 | 0.0 |
Microsomes, Liver/*drug effects/*enzymology | 3 | 60.0 |
Liver/cytology/*metabolism | 3 | 4.0 |
Serotonin Agonists/*metabolism | 2 | 100.0 |
Cytochrome P-450 CYP2D6/genetics/metabolism | 7 | 46.0 |
Tacrine/*diagnostic use/pharmacokinetics | 2 | 100.0 |
Single-Blind Method | 3 | 1.0 |
Menstrual Cycle/metabolism | 2 | 9.0 |
*Pharmacology | 2 | 50.0 |
*Sex Factors | 2 | 14.0 |
Acetaminophen/blood/*pharmacokinetics | 2 | 100.0 |
Phenacetin/blood/*pharmacokinetics | 2 | 100.0 |
Serotonin Uptake Inhibitors/pharmacology | 2 | 16.0 |
Chromosome Aberrations | 2 | 0.0 |
Deoxyguanosine/*analogs & derivatives/urine | 3 | 50.0 |
Antineoplastic Agents, Hormonal/metabolism/toxicity | 2 | 100.0 |
Benzo(a)pyrene/metabolism/*toxicity | 3 | 60.0 |
Cardiotonic Agents/metabolism/toxicity | 2 | 100.0 |
Digitoxin/metabolism/toxicity | 2 | 100.0 |
Disease Susceptibility/chemically induced/metabolism | 2 | 100.0 |
Endocrine System/drug effects | 2 | 20.0 |
Estrogens/metabolism/toxicity | 2 | 100.0 |
Heterocyclic Compounds/metabolism/*toxicity | 2 | 100.0 |
Neoplasms/*chemically induced/metabolism | 2 | 100.0 |
Tamoxifen/metabolism/toxicity | 2 | 100.0 |
Acetonitriles | 2 | 50.0 |
Antibodies, Monoclonal/pharmacology | 4 | 0.0 |
Cytochrome P-450 Enzyme System/analysis/genetics/*metabolism | 2 | 100.0 |
Dimethylformamide | 2 | 100.0 |
Flunitrazepam/*metabolism | 2 | 40.0 |
*Ginsenosides | 2 | 22.0 |
Panax/*chemistry | 2 | 18.0 |
Saponins/*pharmacology | 2 | 20.0 |
Biliary Tract/*enzymology | 2 | 100.0 |
Epoxide Hydrolases/genetics/metabolism | 4 | 66.0 |
Gallbladder/cytology/*enzymology | 2 | 100.0 |
Liver/cytology/enzymology | 3 | 37.0 |
Oxidoreductases, N-Demethylating/genetics/metabolism | 7 | 38.0 |
RNA, Messenger/analysis/genetics | 2 | 0.0 |
B-Lymphocytes | 2 | 1.0 |
Isoenzymes/genetics/*metabolism | 6 | 6.0 |
Culture Techniques | 4 | 0.0 |
Fentanyl/*metabolism | 2 | 100.0 |
NADPH-Ferrihemoprotein Reductase/genetics | 2 | 40.0 |
Antibodies, Monoclonal | 2 | 0.0 |
Cytochrome P-450 Enzyme System/*analysis/immunology | 2 | 50.0 |
Mutagens/*metabolism | 13 | 35.0 |
Quinoxalines/*metabolism | 5 | 55.0 |
Imipramine/*pharmacokinetics | 2 | 50.0 |
Chlorzoxazone/*pharmacokinetics | 2 | 33.0 |
Cross Reactions | 3 | 0.0 |
Haplorhini | 3 | 1.0 |
Antimutagenic Agents/*pharmacology | 2 | 13.0 |
Steroid Hydroxylases/genetics/metabolism | 2 | 18.0 |
*Thiazolidinediones | 3 | 3.0 |
Chromatography, Gas | 2 | 2.0 |
DNA/genetics | 5 | 0.0 |
Drug Resistance | 3 | 0.0 |
Fluorescent Dyes | 3 | 0.0 |
Hepatocytes/enzymology | 3 | 20.0 |
Indoles/metabolism/pharmacology | 2 | 33.0 |
Smoking/adverse effects | 7 | 2.0 |
Anti-Arrhythmia Agents/metabolism/*pharmacokinetics | 2 | 100.0 |
Specimen Handling/*methods | 2 | 10.0 |
Theophylline/blood/*pharmacokinetics | 2 | 100.0 |
Aminobiphenyl Compounds/pharmacokinetics/*toxicity | 2 | 100.0 |
Animals, Newborn | 4 | 0.0 |
Organ Size/drug effects | 2 | 2.0 |
Fishes | 2 | 2.0 |
Polychlorinated Biphenyls/*pharmacology | 2 | 14.0 |
Hypnotics and Sedatives/*metabolism | 4 | 57.0 |
Adrenergic beta-Antagonists/*metabolism | 3 | 75.0 |
Escherichia coli/*enzymology | 2 | 12.0 |
Recombinant Proteins/chemistry/metabolism | 2 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction/*methods | 2 | 3.0 |
Antidepressive Agents/*pharmacokinetics | 2 | 66.0 |
Biotransformation/genetics | 3 | 33.0 |
Anticoagulants/*metabolism | 2 | 6.0 |
Aryl Hydrocarbon Hydroxylases/*genetics | 4 | 3.0 |
Drug Interactions/genetics | 2 | 50.0 |
Warfarin/*metabolism | 3 | 60.0 |
Xanthine Oxidase/genetics/metabolism | 2 | 100.0 |
*Drug Interactions | 6 | 26.0 |
Injections, Intravenous | 3 | 0.0 |
Antibodies, Blocking/pharmacology | 2 | 2.0 |
Cell Survival/drug effects/physiology | 2 | 2.0 |
Formazans/metabolism | 2 | 40.0 |
Tetrazolium Salts/metabolism | 2 | 12.0 |
Anticonvulsants/*pharmacokinetics | 2 | 20.0 |
Chromatography, High Pressure Liquid/*methods | 4 | 3.0 |
Theophylline/*blood | 2 | 66.0 |
Actins/biosynthesis | 2 | 4.0 |
Cytochrome P-450 CYP1A1/biosynthesis | 4 | 13.0 |
Isoenzymes/biosynthesis | 3 | 6.0 |
DNA Probes | 2 | 0.0 |
Pyridines/*metabolism | 3 | 30.0 |
Intestine, Small/metabolism | 3 | 5.0 |
P-Glycoprotein/*metabolism | 2 | 2.0 |
Coffee | 6 | 50.0 |
Clomipramine/*metabolism | 2 | 100.0 |
Caffeine | 2 | 40.0 |
Cytochrome P-450 CYP1A2/*blood | 2 | 100.0 |
Aryl Hydrocarbon Hydroxylases/antagonists & inhibitors | 2 | 100.0 |
Thiazoles/pharmacology | 3 | 2.0 |
Cytochrome P-450 Enzyme System/analysis | 3 | 33.0 |
H(+)-K(+)-Exchanging ATPase/*antagonists & inhibitors | 3 | 33.0 |
Omeprazole/analogs & derivatives | 3 | 20.0 |
Proton Pumps/antagonists & inhibitors | 2 | 14.0 |
Mixed Function Oxygenases/*physiology | 6 | 19.0 |
Cytochrome P-450 CYP1A2/*urine | 2 | 100.0 |
Benzo(a)pyrene/*pharmacology | 3 | 30.0 |
Escherichia coli/enzymology/*genetics | 2 | 11.0 |
Mutagens/pharmacology | 2 | 5.0 |
Biological Markers/*urine | 2 | 16.0 |
*DNA Damage | 4 | 0.0 |
Denmark | 3 | 1.0 |
Ultraviolet Rays | 2 | 0.0 |
Anti-Anxiety Agents/*pharmacokinetics | 2 | 16.0 |
Central Nervous System Stimulants/pharmacokinetics | 3 | 100.0 |
Methylation/drug effects | 3 | 21.0 |
Epoxy Compounds/metabolism | 2 | 25.0 |
Oxygen/metabolism | 3 | 1.0 |
Isoenzymes/antagonists & inhibitors/immunology/metabolism | 3 | 100.0 |
COS Cells | 3 | 0.0 |
Cytochrome P-450 CYP1A2/antagonists & inhibitors/genetics/*metabolism | 2 | 100.0 |
Uric Acid/analogs & derivatives/metabolism | 4 | 100.0 |
Xanthines/metabolism | 3 | 60.0 |
Solubility | 4 | 0.0 |
Amines/*metabolism | 3 | 16.0 |
DNA Adducts/analysis/*metabolism | 2 | 66.0 |
Heterocyclic Compounds/*metabolism | 6 | 60.0 |
Cytochrome P-450 CYP1A1/antagonists & inhibitors/*metabolism | 2 | 100.0 |
Enzyme Inhibitors/*pharmacokinetics | 2 | 18.0 |
Hepatocytes/drug effects/*enzymology | 2 | 18.0 |
Saccharomyces cerevisiae | 2 | 0.0 |
Caffeine/*pharmacokinetics/urine | 2 | 100.0 |
Prothrombin Time | 3 | 2.0 |
Fluvoxamine/blood/*pharmacokinetics | 2 | 100.0 |
Central Nervous System Stimulants/metabolism | 2 | 100.0 |
Polymorphism, Restriction Fragment Length | 7 | 0.0 |
Anti-Ulcer Agents/*pharmacology | 2 | 9.0 |
Receptors, Aryl Hydrocarbon/physiology | 2 | 22.0 |
Regression Analysis | 13 | 0.0 |
Microsomes, Liver/drug effects/enzymology/*metabolism | 4 | 22.0 |
Mixed Function Oxygenases/antagonists & inhibitors/immunology/*metabolism | 2 | 40.0 |
Flavonoids/chemistry/*pharmacology | 2 | 15.0 |
Uric Acid/analogs & derivatives/urine | 3 | 75.0 |
DNA, Complementary/genetics/metabolism | 2 | 4.0 |
Isoxazoles/*metabolism | 2 | 66.0 |
Pyrimidines/*metabolism | 2 | 28.0 |
Caffeine/metabolism/*urine | 5 | 83.0 |
Genetic Vectors | 7 | 0.0 |
Tetrachlorodibenzodioxin/*toxicity | 4 | 8.0 |
Isoenzymes/genetics/*physiology | 2 | 22.0 |
Mutagens/*pharmacokinetics | 2 | 25.0 |
Midazolam/pharmacokinetics | 2 | 16.0 |
Lethal Dose 50 | 2 | 3.0 |
Mice, Inbred BALB C | 4 | 0.0 |
Microsomes/enzymology/metabolism | 2 | 11.0 |
Aging/*urine | 2 | 40.0 |
Theophylline/administration & dosage/*pharmacokinetics | 2 | 50.0 |
Imidazoles/*metabolism | 8 | 25.0 |
Fetus/*metabolism | 2 | 2.0 |
Enzyme Induction/*drug effects | 4 | 23.0 |
Saccharomyces cerevisiae/genetics | 3 | 0.0 |
Antineoplastic Agents/*pharmacology | 4 | 0.0 |
Organ Culture Techniques | 3 | 0.0 |
Benz(a)Anthracenes/pharmacology | 2 | 40.0 |
Methylcholanthrene/*pharmacology | 4 | 50.0 |
Tetrachlorodibenzodioxin/*pharmacology | 4 | 6.0 |
*Pharmacogenetics | 4 | 8.0 |
Recombinant Fusion Proteins/metabolism | 2 | 0.0 |
Cytochrome P-450 CYP1A1/*antagonists & inhibitors | 3 | 50.0 |
Oxidoreductases, N-Demethylating/antagonists & inhibitors | 4 | 36.0 |
Disulfiram/*pharmacokinetics | 2 | 100.0 |
Cytochrome P-450 CYP1A2/*biosynthesis/drug effects | 3 | 100.0 |
Indoles/*pharmacology | 2 | 2.0 |
Etoposide/*metabolism | 2 | 100.0 |
Isoenzymes/physiology | 4 | 8.0 |
Antibodies, Viral/immunology | 3 | 3.0 |
Bone Neoplasms/pathology/virology | 3 | 50.0 |
Carcinoma, Squamous Cell/etiology/*genetics/pathology/virology | 3 | 50.0 |
Cell Line, Tumor/metabolism/virology | 3 | 42.0 |
Cell Nucleus/virology | 3 | 23.0 |
Cell Transformation, Neoplastic/genetics | 3 | 1.0 |
Cell Transformation, Viral/genetics | 3 | 12.0 |
Cervical Intraepithelial Neoplasia/etiology/*genetics/pathology/virology | 3 | 50.0 |
Cervix Neoplasms/etiology/*genetics/pathology/virology | 3 | 50.0 |
Cervix Uteri/pathology/*virology | 3 | 42.0 |
Disease Progression | 3 | 0.0 |
Epithelial Cells/ultrastructure/virology | 3 | 50.0 |
*Gene Expression Regulation, Neoplastic | 3 | 0.0 |
*Gene Expression Regulation, Viral | 3 | 1.0 |
Genes, Retinoblastoma | 3 | 3.0 |
Oncogene Proteins, Viral/biosynthesis/genetics/immunology/*physiology | 3 | 50.0 |
Osteosarcoma/pathology/virology | 3 | 50.0 |
Papillomavirus Infections/*genetics | 3 | 37.0 |
Papillomavirus, Human/genetics/*pathogenicity | 3 | 37.0 |
Retinoblastoma Protein/*metabolism | 3 | 1.0 |
Tumor Virus Infections/*genetics | 3 | 27.0 |
Depressive Disorder/*drug therapy | 2 | 28.0 |
NADPH-Ferrihemoprotein Reductase | 2 | 15.0 |
Oxidoreductases/*antagonists & inhibitors | 5 | 45.0 |
Liver/drug effects/enzymology/pathology | 2 | 66.0 |
Smoking/*metabolism | 4 | 9.0 |
Glucuronosyltransferase/metabolism | 3 | 11.0 |
Xenobiotics/pharmacokinetics | 2 | 28.0 |
NADH, NADPH Oxidoreductases/drug effects | 2 | 100.0 |
Terpenes/*pharmacology | 3 | 15.0 |
HIV Protease Inhibitors/*pharmacology | 2 | 7.0 |
Chemical Fractionation | 2 | 2.0 |
Aflatoxin B1/toxicity | 4 | 44.0 |
Benzo(a)pyrene/toxicity | 3 | 18.0 |
Cytochrome P-450 CYP1A2/*biosynthesis/*genetics/metabolism | 2 | 100.0 |
Oxygenases/metabolism | 2 | 25.0 |
Cytochrome P-450 Enzyme System/*antagonists & inhibitors/physiology | 4 | 57.0 |
Infusions, Intravenous | 5 | 0.0 |
Kidney/*metabolism | 2 | 1.0 |
Cytochrome P-450 Enzyme System/analysis/*metabolism | 2 | 28.0 |
Isoenzymes/biosynthesis/*metabolism | 4 | 44.0 |
Caffeine/metabolism/urine | 3 | 75.0 |
Theophylline/*analogs & derivatives/metabolism/pharmacology | 2 | 100.0 |
Protein Biosynthesis | 4 | 0.0 |
Cytochrome P-450 Enzyme System/*biosynthesis/metabolism | 4 | 30.0 |
Smoke/*adverse effects | 3 | 15.0 |
Promoter Regions (Genetics) | 3 | 0.0 |
Blood Loss, Surgical/statistics & numerical data | 3 | 12.0 |
Blood Transfusion/utilization | 3 | 12.0 |
Cost-Benefit Analysis | 3 | 2.0 |
Hospital Costs/statistics & numerical data | 3 | 12.0 |
Length of Stay/statistics & numerical data | 3 | 8.0 |
Osteoarthritis, Knee/epidemiology/*surgery | 3 | 13.0 |
*Outcome Assessment (Health Care) | 3 | 6.0 |
Perioperative Care | 3 | 12.0 |
Postoperative Complications/epidemiology | 3 | 6.0 |
Turkey/epidemiology | 3 | 4.0 |
Micronuclei, Chromosome-Defective | 2 | 18.0 |
Down-Regulation | 2 | 0.0 |
Liver/cytology/*drug effects/enzymology | 2 | 16.0 |
Chromatography, Liquid/methods | 2 | 9.0 |
Plasmids/genetics | 2 | 0.0 |
Isoenzymes/*physiology | 3 | 9.0 |
Breath Tests | 9 | 12.0 |
Anticholesteremic Agents/pharmacology | 2 | 4.0 |
Antibodies/immunology | 2 | 0.0 |
*Dose-Response Relationship, Drug | 2 | 40.0 |
Mutagens/pharmacokinetics/*toxicity | 3 | 50.0 |
Recombinant Proteins/biosynthesis/metabolism | 4 | 2.0 |
Blotting, Southern | 2 | 0.0 |
Carbon Dioxide/metabolism | 2 | 6.0 |
Transcription, Genetic/drug effects | 2 | 0.0 |
Sertraline | 5 | 50.0 |
Aryl Hydrocarbon Hydroxylases/genetics/metabolism | 5 | 27.0 |
Micronuclei, Chromosome-Defective/drug effects | 2 | 33.0 |
Pedigree | 2 | 0.0 |
Protein Synthesis Inhibitors/pharmacology | 2 | 0.0 |
RNA/biosynthesis | 2 | 2.0 |
Clozapine/analogs & derivatives/*metabolism | 2 | 100.0 |
Cytochrome P-450 Enzyme System/biosynthesis/*genetics/*metabolism | 2 | 25.0 |
Arachidonic Acid/*metabolism | 2 | 5.0 |
Acetyltransferases/genetics | 2 | 5.0 |
Cytochrome P-450 Enzyme System/biosynthesis | 3 | 15.0 |
Oxidoreductases/biosynthesis | 2 | 50.0 |
Dextromethorphan/diagnostic use | 2 | 100.0 |
DNA, Complementary/*genetics | 3 | 1.0 |
Polymorphism, Genetic/genetics | 7 | 1.0 |
Anti-Arrhythmia Agents/*pharmacokinetics | 2 | 33.0 |
Depressive Disorder/drug therapy/metabolism | 3 | 75.0 |
Kidney Diseases/metabolism | 2 | 7.0 |
Liver Diseases/metabolism | 2 | 11.0 |
Enhancer Elements (Genetics) | 2 | 0.0 |
Indoles/pharmacology | 2 | 0.0 |
Hormone Antagonists/*metabolism | 2 | 100.0 |
Norpregnenes/pharmacology | 2 | 22.0 |
Glucuronates/metabolism | 2 | 7.0 |
Riluzole | 2 | 66.0 |
Carbon Radioisotopes | 2 | 2.0 |
Antibodies/immunology/*pharmacology | 2 | 28.0 |
Immune Sera/immunology | 2 | 1.0 |
1-Naphthylamine/analogs & derivatives/pharmacokinetics | 2 | 100.0 |
Fluoxetine/pharmacokinetics | 2 | 66.0 |
Fluvoxamine/pharmacokinetics | 2 | 100.0 |
Paroxetine/pharmacokinetics | 2 | 66.0 |
Liver/cytology/drug effects/*enzymology | 2 | 25.0 |
Heat | 3 | 0.0 |
Quinoxalines/*urine | 2 | 50.0 |
Recombinant Proteins/immunology/metabolism | 2 | 4.0 |
Calcium Channel Blockers/*metabolism | 2 | 50.0 |
Cytochrome P-450 Enzyme System/*antagonists & inhibitors/*biosynthesis | 2 | 66.0 |
Glutathione Transferase/metabolism | 4 | 0.0 |
Risk | 2 | 0.0 |
Microsomes, Liver/immunology | 2 | 50.0 |
Injections, Intraperitoneal | 2 | 1.0 |
Isoflavones/*pharmacology | 2 | 8.0 |
Monoamine Oxidase Inhibitors/*pharmacology | 2 | 22.0 |
Serotonin Uptake Inhibitors/pharmacokinetics/*pharmacology | 2 | 100.0 |
Mephenytoin/*metabolism | 2 | 22.0 |
Microsomes/*metabolism | 2 | 4.0 |
Cytochrome P-450 Enzyme System/genetics/immunology/*metabolism | 2 | 33.0 |
Acetaminophen/*metabolism | 2 | 40.0 |
Cytochrome P-450 Enzyme System/*antagonists & inhibitors/genetics | 3 | 50.0 |
Intestines/enzymology | 2 | 11.0 |
Isoenzymes/*antagonists & inhibitors/metabolism | 2 | 20.0 |
Methoxychlor/*metabolism | 2 | 40.0 |
Transcription Factors/*physiology | 2 | 0.0 |
Up-Regulation | 2 | 0.0 |
Toluene/*metabolism | 2 | 25.0 |
Electrophoresis | 2 | 0.0 |
Theophylline/*metabolism | 3 | 60.0 |
Aryl Hydrocarbon Hydroxylases/antagonists & inhibitors/metabolism | 2 | 28.0 |
Isoenzymes/immunology/*metabolism | 2 | 33.0 |
Aflatoxin B1/*metabolism | 3 | 37.0 |
DNA Adducts/metabolism | 2 | 5.0 |
CHO Cells | 2 | 0.0 |
NADPH-Ferrihemoprotein Reductase/biosynthesis | 2 | 66.0 |
Lung/enzymology | 2 | 3.0 |
Genes, Reporter | 2 | 0.0 |
Indoles/*metabolism | 2 | 18.0 |
Receptors, Aryl Hydrocarbon/*metabolism | 4 | 5.0 |
Antipsychotic Agents/*blood/therapeutic use | 2 | 50.0 |
Cell Division/physiology | 2 | 0.0 |
Transformation, Genetic | 3 | 1.0 |
Liver/*drug effects/*enzymology | 4 | 50.0 |
Indoles/administration & dosage/*pharmacology | 2 | 33.0 |
Bladder Neoplasms/etiology | 2 | 28.0 |
Theophylline/metabolism/urine | 2 | 100.0 |
Propranolol/*metabolism | 3 | 100.0 |
Adrenergic Agents/pharmacokinetics | 2 | 100.0 |
Debrisoquin/pharmacokinetics | 2 | 50.0 |
Placenta/*enzymology | 2 | 2.0 |
Aflatoxin B1/*toxicity | 2 | 33.0 |
Organ Specificity | 3 | 0.0 |
Antidepressive Agents, Second-Generation/*pharmacokinetics | 2 | 100.0 |
Citalopram/pharmacokinetics | 2 | 100.0 |
Antipsychotic Agents/chemistry/*metabolism | 2 | 100.0 |
Phenothiazines/chemistry/*metabolism | 2 | 100.0 |
Enzyme Inhibitors/metabolism | 2 | 0.0 |
Vaccinia virus/genetics | 3 | 4.0 |
Cytochrome P-450 CYP2E1/*genetics/metabolism | 2 | 9.0 |
Acetyltransferases/*metabolism | 5 | 6.0 |
Contraceptives, Oral, Hormonal/adverse effects | 2 | 15.0 |
Cytochrome P-450 CYP1A2 | 79 | 91.0 |
2-Acetylaminofluorene/*toxicity | 2 | 50.0 |
Thiazoles/*pharmacology | 2 | 3.0 |
Benzimidazoles/administration & dosage/*pharmacokinetics | 2 | 100.0 |
Sulfoxides/administration & dosage/*pharmacokinetics | 2 | 100.0 |
Cytochrome P-450 Enzyme System/*immunology | 2 | 28.0 |
P-Glycoprotein/*genetics | 2 | 4.0 |
Oxidoreductases/*physiology | 2 | 100.0 |
Cytochrome P-450 CYP1A2/*chemistry | 3 | 100.0 |
Recombinant Proteins/chemistry | 2 | 0.0 |
Caffeine/blood/*metabolism/urine | 4 | 100.0 |
Biological Markers/blood/urine | 2 | 4.0 |
Computer Simulation | 3 | 0.0 |
Caffeine/*diagnostic use | 2 | 66.0 |
Fluoxetine/pharmacology | 2 | 33.0 |
Isotope Labeling | 2 | 2.0 |
Oxidoreductases/drug effects | 2 | 50.0 |
Theophylline/biosynthesis | 2 | 100.0 |
Oxidoreductases/*metabolism | 11 | 26.0 |
Cytochrome P-450 CYP1A1 | 8 | 19.0 |
Oxidoreductases/physiology | 2 | 66.0 |
Carcinogens/metabolism/*toxicity | 2 | 20.0 |
DNA/*drug effects/metabolism | 3 | 42.0 |
Erythromycin/pharmacology | 2 | 12.0 |
Food Handling | 2 | 15.0 |
Oxidoreductases/genetics/*metabolism | 8 | 40.0 |
Liver/*enzymology/metabolism | 2 | 12.0 |
Oxazines/chemistry/*metabolism | 2 | 100.0 |
beta-Naphthoflavone | 5 | 27.0 |
Heterozygote | 3 | 0.0 |
Moclobemide | 2 | 50.0 |
Amines/metabolism | 2 | 15.0 |
Nitrosamines/metabolism | 2 | 33.0 |
Cytokines/*pharmacology | 2 | 0.0 |
Interleukin-1/pharmacology | 2 | 0.0 |
Interleukin-6/pharmacology | 2 | 0.0 |
Tumor Necrosis Factor-alpha/pharmacology | 2 | 0.0 |
Oxidoreductases/*analysis | 3 | 37.0 |
Enzyme Activation/physiology | 2 | 1.0 |
Cytochrome P-450 CYP2E1 | 6 | 5.0 |
Cytochrome P-450 Enzyme System/*antagonists & inhibitors/immunology | 2 | 100.0 |
Epoxide Hydrolases/genetics/*metabolism | 3 | 60.0 |
Phosphodiesterase Inhibitors/pharmacology | 3 | 2.0 |
Exons | 3 | 0.0 |
Recombination, Genetic | 2 | 0.0 |
Oxidoreductases/*genetics | 3 | 3.0 |
Vaccinia virus | 2 | 9.0 |
Oxidoreductases/*genetics/metabolism | 2 | 10.0 |
Mutation/genetics | 2 | 0.0 |
Oxidoreductases/genetics | 2 | 5.0 |
Variation (Genetics)/*genetics | 3 | 1.0 |
Oxidoreductases/genetics/metabolism | 2 | 16.0 |
Antibody Affinity | 2 | 1.0 |
Imipramine/metabolism | 2 | 50.0 |
Carcinogens/*metabolism/toxicity | 4 | 25.0 |
*Food | 2 | 2.0 |
Mutagens/*metabolism/toxicity | 2 | 50.0 |
Environmental Pollutants | 2 | 40.0 |
Caffeine/administration & dosage/pharmacokinetics/*urine | 2 | 100.0 |
Oxidoreductases/*biosynthesis/genetics | 2 | 50.0 |
Oxidoreductases/biosynthesis/*metabolism | 3 | 100.0 |
DNA, Complementary/biosynthesis/genetics | 3 | 6.0 |
Oxygenases/*metabolism | 3 | 12.0 |
Oxidoreductases/*biosynthesis | 2 | 25.0 |
Oxidoreductases/*urine | 2 | 100.0 |
Cytochrome P-450 Enzyme System/analysis/*physiology | 2 | 50.0 |
Oxidoreductases/analysis/*physiology | 2 | 100.0 |
Ethylene Glycols/metabolism | 2 | 40.0 |
Styrene | 2 | 28.0 |
Blood Pressure/drug effects | 2 | 0.0 |
Caffeine/pharmacology | 2 | 2.0 |
Heart Rate/drug effects | 3 | 1.0 |
Benzoflavones/metabolism/*pharmacology | 2 | 66.0 |
Environmental Pollutants/*toxicity | 2 | 5.0 |
Oxidoreductases/antagonists & inhibitors/metabolism | 2 | 50.0 |
Mutation/*genetics | 3 | 0.0 |
Benzofurans/*metabolism | 2 | 66.0 |
Aryl Hydrocarbon Hydroxylases/*antagonists & inhibitors | 3 | 18.0 |
Mesocricetus | 2 | 1.0 |
Catechols/*metabolism | 2 | 50.0 |
Trimethadione/*metabolism | 2 | 50.0 |
Gene Expression Regulation, Enzymologic/*drug effects/physiology | 2 | 33.0 |
Epitopes/*analysis | 2 | 1.0 |
Evaluation Studies | 2 | 0.0 |
Aryl Hydrocarbon Hydroxylases/*physiology | 2 | 33.0 |
Nitric Oxide/metabolism | 2 | 1.0 |
Oxidoreductases, N-Demethylating/*physiology | 2 | 20.0 |
Oxidoreductases, O-Demethylating/metabolism | 2 | 100.0 |
Blood Proteins/metabolism | 3 | 1.0 |
Caffeine/metabolism/*pharmacokinetics | 2 | 100.0 |
Drugs, Chinese Herbal/*pharmacology | 2 | 4.0 |
Glucuronides/metabolism | 2 | 4.0 |
Neoplasms/*chemically induced/genetics | 2 | 66.0 |
Carcinogens | 2 | 2.0 |
Gene Expression/*genetics | 2 | 1.0 |
Saccharomyces cerevisiae/enzymology/*genetics | 2 | 7.0 |
Italy | 2 | 0.0 |
Carcinoma, Hepatocellular/*metabolism | 2 | 1.0 |
DNA/*metabolism | 2 | 0.0 |
Gene Expression Regulation | 3 | 0.0 |
*Amino Acid Transport Systems | 2 | 16.0 |
Rifampin/*pharmacology | 2 | 4.0 |
Isoenzymes/genetics | 3 | 0.0 |
Chronic Disease | 2 | 0.0 |
*Contrast Media | 2 | 7.0 |
*Tobacco | 2 | 8.0 |
Aryl Hydrocarbon Hydroxylases/antagonists & inhibitors/*biosynthesis | 2 | 66.0 |
Promoter Regions (Genetics)/genetics | 2 | 0.0 |
Polymerase Chain Reaction/methods | 4 | 0.0 |
Prevalence | 2 | 0.0 |
Spectrometry, Mass, Electrospray Ionization/*methods | 2 | 14.0 |
Methylcholanthrene/toxicity | 2 | 40.0 |
5' Flanking Region/*genetics | 2 | 7.0 |
Metabolic Clearance Rate/drug effects/physiology | 3 | 25.0 |
Cytochrome P-450 CYP1A1/antagonists & inhibitors/*biosynthesis | 2 | 100.0 |
Cytochrome P-450 CYP1A2/antagonists & inhibitors/*biosynthesis | 2 | 100.0 |
Drug Evaluation, Preclinical/methods | 2 | 6.0 |
Genetic Predisposition to Disease/genetics | 2 | 0.0 |
Mutagens/toxicity | 2 | 5.0 |
Linkage Disequilibrium | 2 | 0.0 |
Calibration | 2 | 1.0 |
Gene Frequency/genetics | 3 | 0.0 |
